Ignite Creation Date:
2024-05-06 @ 1:03 PM
Last Modification Date:
2024-10-26 @ 1:08 PM
Study NCT ID:
NCT03922100
Status:
TERMINATED
Last Update Posted:
2024-02-21
First Post:
2019-04-04
Brief Title:
Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML
Sponsor:
Nerviano Medical Sciences
Organization:
Nerviano Medical Sciences
Study Overview
Official Title:
A Phase III Study of NMS-03592088 a FLT3 KIT and CSF1R Inhibitor in Patients With Relapsed or Refractory AML or CMML
Status:
TERMINATED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study stopped due to strategic reasons The decision is not based on specific safety findings as the safety observed in the phase II part of the study is in line with what was reported in the phase I part
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to explore safety tolerability including the maximum tolerated dose and the recommended Phase II dose RP2D and antitumor activity of NMS-03592088 in adult patients with relapsed or refractory Acute Myeloid Leukemia AML or Chronic Myelomonocytic Leukemia CMML
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2018-002793-47 | EUDRACT_NUMBER | None | None |